A cancer drug enters the body with a job to do. But its success may depend partly on a bustling community far from the tumor — the microbes living in the digestive tract. And those microscopic residents have their own needs, starting with what’s on the menu.
That connection could help explain a puzzle that has intrigued cancer researchers for years. Why do some people with a higher body mass index respond better to certain immunotherapies?